Cargando…

A185 SUSTAINED SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-2 MAINTENANCE TRIAL

BACKGROUND: Mirikizumab (miri) improved symptom control in a Phase 3, multicenter, randomized, double-blind, parallel, placebo-controlled induction study at Week (W)12, in patients (pts) with moderately-to-severely active ulcerative colitis (UC; LUCENT-1). PURPOSE: This analysis assessed sustained s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dignass, A, Danese, S, Matsuoka, K, Ferrante, M, Long, M, Redondo, I, Gibble, T H, Moses, R, Li, X, Morris, N, Milch, C, Abreu, M, Jones, J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Poster Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9991200/ http://dx.doi.org/10.1093/jcag/gwac036.185

Ejemplares similares

A184 EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-1 INDUCTION TRIAL
por: Danese, S, et al.
Publicado: (2023)

Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes
por: Magro, Fernando, et al.
Publicado: (2023)

Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies
por: Sands, Bruce E, et al.
Publicado: (2023)

Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies
por: Chua, Laiyi, et al.
Publicado: (2023)

A201 EFFECT OF MIRIKIZUMAB ON BOWEL URGENCY CLINICALLY MEANINGFUL IMPROVEMENT AND REMISSION: RESULTS FROM THE PHASE 3 LUCENT INDUCTION AND MAINTENANCE STUDIES
por: Travis, S, et al.
Publicado: (2023)

A31 MIRIKIZUMAB IMPROVES QUALITY OF LIFE IN MODERATELY-TO-SEVERELY ACTIVE UC: IMPROVEMENT IN IBDQ SCORES IN PARTICIPANTS OF LUCENT-1 AND LUCENT-2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIALS
por: Sands, B E, et al.
Publicado: (2023)

Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease Remission
por: Dubinsky, Marla C, et al.
Publicado: (2022)

Mirikizumab-Induced Transcriptome Changes in Ulcerative Colitis Patient Biopsies at Week 12 Are Maintained Through Week 52
por: Johnson, Travis, et al.
Publicado: (2023)

Lucente stella
Publicado: (1995)

Bowel Urgency in Ulcerative Colitis: Current Perspectives and Future Directions
por: Dubinsky, Marla, et al.
Publicado: (2023)

Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis
por: Dubinsky, Marla C, et al.
Publicado: (2023)

Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study
por: Steere, Boyd, et al.
Publicado: (2023)

International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients
por: Caron, Bénédicte, et al.
Publicado: (2023)

Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study
por: Danese, Silvio, et al.
Publicado: (2016)

Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis
por: Solitano, Virginia, et al.
Publicado: (2020)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis
por: Louis, Edouard, et al.
Publicado: (2022)

iSTART-II: An Update on the i Support Therapy–Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

Decreased myocardial perfusion SPECT lung-to-heart ratio: Lucent lungs
por: Wosnitzer, Brian, et al.
Publicado: (2015)

The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitis
por: Cheon, Jae Hee, et al.
Publicado: (2023)

Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review
por: Caron, Bénédicte, et al.
Publicado: (2022)

Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis
por: Suzuki, Yasuo, et al.
Publicado: (2017)

Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension
por: Abreu, Maria T, et al.
Publicado: (2022)

Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis
por: Panaccione, Remo, et al.
Publicado: (2023)

A145 EFFICACY AND SAFETY OF UPADACITINIB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A RANDOMIZED PHASE 3 STUDY
por: Panaccione, R, et al.
Publicado: (2022)

Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy
por: Napolitano, Maria, et al.
Publicado: (2022)

Composite outcomes in observational studies of ulcerative colitis: A systematic review and meta‐analysis
por: Magro, Fernando, et al.
Publicado: (2021)

Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis)
por: Probert, Christopher SJ, et al.
Publicado: (2018)

Use of granulocyte/monocytapheresis in ulcerative colitis: A practical review from a European perspective
por: Domènech, Eugeni, et al.
Publicado: (2021)

Efficacy of JAK inhibitors in Ulcerative Colitis
por: Ferrante, Marc, et al.
Publicado: (2020)

Omega-3 fatty acids in the maintenance of ulcerative colitis
por: Papadia, Cinzia, et al.
Publicado: (2010)

Ulcerative Colitis-Symptom Questionnaire: Valid for Use in Adults with Moderately to Severely Active Ulcerative Colitis
por: Panes, Julian, et al.
Publicado: (2023)

A186 ASSOCIATION OF ULCERATIVE COLITIS BOWEL URGENCY IMPROVEMENT WITH CLINICAL RESPONSE AND REMISSION
por: Clemow, D B, et al.
Publicado: (2023)

Treatment of Patients with Mild to Moderate Ulcerative Colitis: A Middle East Expert Consensus
por: Awadhi, Sameer Al, et al.
Publicado: (2023)

Budesonide MMX for the Induction of Remission of Mild to Moderate Ulcerative Colitis: A Pooled Safety Analysis
por: Lichtenstein, Gary R., et al.
Publicado: (2015)

Disease clearance in ulcerative colitis: Is the ultimate therapeutic target?
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis
por: Bencardino, Sarah, et al.
Publicado: (2023)

Rapid Induction and Maintenance of Remission in Refractory Ulcerative Colitis with Ustekinumab
por: Chen, An-Yu, et al.
Publicado: (2019)

Assessment of the effectiveness of Budesonide MMX(®) for active, mild-to-moderate ulcerative colitis in the Polish sub-group of the CORE Practice prospective multi-centre observational study
por: Jesionowski, Maciej, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jrq2vn8427bac17nd5buh4fmba